

Freedom of Information Request: Our Reference CTMUHB_398_22

You asked:

Could you please tell me how many patients were treated in September 2022 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olmiant)
- Bimekizumab (Bimzelx)
- Brodalumab (Kyntheum)
- Dupilumab (Dupixent)
- Ixekizumab (Taltz)
- Risankizumab (Skyrizi)
- Guselkumab (Tremfya)
- Secukinumab (Cosentyx)
- Tildrakizumab (Ilumetri)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)
- Ustekinumab (Stelara)

Our response:

Please see provided below a table populated with the data that Medicines Management are able to provide. The period relates to the month of September 2022 as requested.

Medicine	Number of Patients
Abrocitinib (Cibinqo)	**
Baricitinib (Olmiant)	**
Bimekizumab (Bimzelx)	**
Brodalumab (Kyntheum)	5
Dupilumab (Dupixent)	53
Ixekizumab (Taltz)	6
Risankizumab (Skyrizi)	0
Guselkumab (Tremfya)	15
Secukinumab (Cosentyx)	0
Tildrakizumab (Ilumetri)	0
Tralokinumab (Adtralza)	0
Upadacitinib (Rinvoq)	0
Ustekinumab (Stelara)	15

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be

contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.